20 LC 33 8250

House Bill 961

By: Representatives Park of the 101st, McLaurin of the 51st, Holland of the 54th, Robichaux of the 48th, Moore of the 95th, and others

A BILL TO BE ENTITLED AN ACT

- 1 To amend Title 31 of the Official Code of Georgia Annotated, relating to health, so as to
- 2 provide for the identification of high-cost prescription drugs for which the state expends
- 3 significant health care funds; to provide for submission of a list of the identified drugs to the
- 4 Attorney General; to authorize the Attorney General to require certain information from drug
- 5 manufacturers; to provide for an annual report to the General Assembly; to provide for
- 6 confidentiality; to provide for civil penalties for noncompliance; to provide for related
- 7 matters; to repeal conflicting laws; and for other purposes.

8 BE IT ENACTED BY THE GENERAL ASSEMBLY OF GEORGIA:

9 **SECTION 1.**

- 10 Title 31 of the Official Code of Georgia Annotated, relating to health, is amended in
- 11 Chapter 2, relating to the Department of Community Health, by adding a new Code section
- 12 to read as follows:
- 13 "<u>31-2-17.</u>
- 14 (a) The department, in collaboration with the State Board of Pharmacy, shall annually
- 15 <u>identify up to 15 prescription drugs on which the state expends significant health care funds</u>
- 16 for which the wholesale acquisition cost has increased by 50 percent or more over the past
- 17 <u>five years or by 15 percent or more over the past 12 months, creating a substantial public</u>
- interest in understanding the development of the drugs' pricing. The prescription drugs
- 19 <u>identified shall represent different drug classes.</u>
- 20 (b) The department shall provide to the Attorney General a list of those prescription drugs
- 21 <u>identified pursuant to this Code section and the percentage of the wholesale acquisition cost</u>
- 22 <u>increase for each drug, and shall make such information available to the public on the</u>
- 23 <u>department's website.</u>
- 24 (c) For each prescription drug identified pursuant to this Code section, the Attorney
- 25 General shall require the drug's manufacturer to provide a justification for the increase in
- 26 <u>the wholesale acquisition cost of the drug in a format that the Attorney General determines</u>

20 LC 33 8250

27 <u>to be understandable and appropriate. The prescription drug manufacturer shall submit to</u>

- 28 <u>the Attorney General all relevant information and supporting documentation necessary to</u>
- 29 <u>justify the manufacturer's wholesale acquisition cost increase, which may include:</u>
- 30 (1) All factors that have contributed to the wholesale acquisition cost increase;
- 31 (2) The percentage of the total wholesale acquisition cost increase attributable to each
- 32 <u>factor; and</u>
- 33 (3) An explanation of the role of each factor in contributing to the wholesale acquisition
- 34 <u>cost increase.</u>
- 35 (d) Nothing in this Code section shall be construed to restrict the legal ability of a
- 36 <u>prescription drug manufacturer to change prices to the extent permitted under federal law.</u>
- 37 (e) The Attorney General, in consultation with the department, shall provide a report to the
- 38 General Assembly on or before December 1 of each year based on the information received
- 39 <u>from prescription drug manufacturers pursuant to this Code section. The Attorney General</u>
- 40 <u>shall also post such report on the Attorney General's website.</u>
- 41 (f) Information provided to the Attorney General by prescription drug manufacturers
- 42 pursuant to this Code section shall not be subject to Article 4 of Chapter 18 of Title 50,
- 43 <u>relating to open records, and shall not be released in any manner that allows for the</u>
- 44 <u>identification of an individual drug or manufacturer or that is likely to compromise the</u>
- 45 <u>financial, competitive, or proprietary nature of the information.</u>
- 46 (g) The Attorney General may bring a civil action in the superior courts for injunctive
- 47 <u>relief, costs, and attorneys' fees, and to impose on a prescription drug manufacturer that</u>
- 48 <u>fails to provide the information required by this Code section a civil penalty of up to</u>
- 49 \$10,000.00 per violation. Each such failure to provide information shall constitute a
- 50 <u>separate violation.</u>"

SECTION 2.

52 All laws and parts of laws in conflict with this Act are repealed.